A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

NCT04493216 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

161

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision to stop compound development. The decision is not based on any safety or efficacy concerns. It reflects the company strategy for portfolio progression.

Conditions

HIV Infections

Interventions

DRUG: GSK3640254
DRUG: ABC/3TC
DRUG: FTC/TAF
DRUG: Dolutegravir
DRUG: Placebo

Sponsor

ViiV Healthcare